Click here for slides on this topic


Alogliptin

An oral antihyperglycemic agent of the dipeptidyl peptidase-4 (DPP-4) inhibitor class.
The following content matched the glossary term: Alogliptin

ADA 2015: The 75th Scientific Sessions of the American Diabetes Association

Top

Coverage of data from ADA 2015, June 5-9, 2015 in Boston, Massachusetts

CompanionSetType2DiabetesMedications

Top

Patient education companion set featuring handouts on DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and medications used to treat type 2 diabetes (English and Spanish)

Medications Used To Treat Type 2 Diabetes

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose.

Medicamentos para el tratamiento de la diabetes tipo 2

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose—in Spanish.

ADA 2016 Type 2 Diabetes Pharmacologic Therapy

Top

Pharmacologic treatment options for type 2 diabetes from the 2016 ADA guidelines

Clinical Insights in Diabetes Newsletter October 2013

Top

Clinical Insights® in Diabetes newsletter October 2013

Exploring DPP-4 CV safety in SAVOR-TIMI 53 and EXAMINE, CV outcomes in Look AHEAD, relationship between gastric bypass and A1C and cardiometabolic risk factors, metabolic effects of bariatric surgery and medical therapy in STAMPEDE, statin use and diabetes risk, severe hypoglycemia and CVD disease risk.

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Top

White WB, Cannon CP, Heller SR, et al for the EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327-1335.

European Association for the Study of Diabetes (EASD) 49th Annual Meeting 2013 - No Pancreatic Risk in DPP-4 Cardiovascular Safety Studies

Top

NDEI's coverage of the European Association for the Study of Diabetes (EASD) 49th Annual Meeting 2013 from Barcelona, Spain

 

European Association for the Study of Diabetes (EASD) 49th Annual Meeting 2013

Top

NDEI's coverage of the European Association for the Study of Diabetes (EASD) 49th Annual Meeting 2013 from Barcelona, Spain

1 2 Next 

Slide Library Results

Search Results for: Alogliptin Slides Found: 20
Alogliptin Monotherapy: A1C
Alogliptin and Glyburide Combination Therapy: A1C
Alogliptin Added to Metformin: A1C
Alogliptin Added to Insulin: A1C
Alogliptin Study 010, Primary Endpoint: Change in A1C at 26 Weeks
Alogliptin Study 010: Secondary Measurements of A1C at Week 26
Alogliptin Study 010, Secondary Efficacy Endpoint at Week 26: Hyperglycemia
Alogliptin Study 010: Exploratory Endpoints of Alogliptin Therapy vs Placebo
Alogliptin Study 010: Safety
DPP-4 Inhibitors: Dosage Adjustment by Degree of Renal Impairment
EXAMINE: No Increase in CV Events with Alogliptin Primary Endpoint
EXAMINE: No Increase in CV Events with Alogliptin Secondary Endpoint
EXAMINE: Significantly Greater A1C Change from Baseline with Alogliptin Vs Placebo
EXAMINE: Adverse Events
EXAMINE: Design
Risk of Acute Pancreatitis Rare in Incretin-Treated Type 2 Diabetes | NDEI
Incretins Therapies & Heart Failure Risk in Type 2 Diabetes PPT | NDEI
TECOS Heart Failure Sitaliptin DPP-4 CV Safety | NDEI
Relationship Between DPP-4 Inhibitors & Heart Failure Diabetes | NDEI
Effect of DPP-4 Inhibitors Vs Placebo on Heart Failure in Diabetes | NDEI